Hovakimyan Marine, Guthoff Rudolf F, Stachs Oliver
Department of Ophthalmology, University of Rostock, Doberaner Strasse 140, 18057 Rostock, Germany.
J Ophthalmol. 2012;2012:406850. doi: 10.1155/2012/406850. Epub 2012 Jan 12.
Collagen cross-linking (CXL) using UVA light and riboflavin (vitamin B2) was introduced as a clinical application to stabilize the cornea by inducing cross-links within and between collagen fibers. CXL has been investigated extensively and has been shown clinically to arrest the progression of keratoconic or post-LASIK ectasia. With its minimal cost, simplicity, and proven positive clinical outcome, CXL can be regarded as a useful approach to reduce the number of penetrating keratoplasties performed. Small case series have also indicated that CXL is beneficial in corneal edema by reducing stromal swelling behavior and in keratitis by inhibiting pathogen growth. Despite these encouraging results, CXL remains a relatively new method that is potentially associated with complications. Aspects such as side effects and recurrence rates have still to be elucidated. In light of the growing interest in CXL, our paper summarizes present knowledge about this promising approach. We have intentionally endeavored to include the more relevant studies from the recent literature to provide an overview of the current status of CXL.
使用紫外线A（UVA）光和核黄素（维生素B2）进行的胶原交联（CXL）作为一种临床应用被引入，通过诱导胶原纤维内部和之间的交联来稳定角膜。CXL已得到广泛研究，并在临床上已显示可阻止圆锥角膜或准分子激光原位角膜磨镶术（LASIK）后角膜扩张的进展。凭借其成本低廉、操作简单且已证实的积极临床效果，CXL可被视为一种减少穿透性角膜移植手术数量的有用方法。小病例系列研究还表明，CXL通过减少基质肿胀行为对角膜水肿有益，并且通过抑制病原体生长对角膜炎有益。尽管有这些令人鼓舞的结果，但CXL仍然是一种相对较新的方法，可能会伴有并发症。诸如副作用和复发率等方面仍有待阐明。鉴于对CXL的兴趣日益增加，我们的论文总结了关于这种有前景方法的现有知识。我们特意努力纳入近期文献中更相关的研究，以概述CXL的当前状况。
